MK-801 has neuroprotective and antiproliferative effects in retinal laser injury

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 7, 1997, Pages 1380-1389

  Solberg, Yoram ^a,b   Rosner, Mordechi ^a   Turetz, Joseph ^a   Belkin, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Glutamate; Laser photocoagulation; MK 801; NMDA; Retina

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ARGON LASER; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; LASER COAGULATION; NEUROPROTECTION; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; RAT; RETINA INJURY; VISUAL IMPAIRMENT;

ANIMALS; CELL DIVISION; DIZOCILPINE MALEATE; LASER COAGULATION; NEUROPROTECTIVE AGENTS; PHOTORECEPTORS; RADIATION INJURIES, EXPERIMENTAL; RATS; RATS, INBRED STRAINS; RECEPTORS, N-METHYL-D-ASPARTATE; RETINA;

EID: 0030961225     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Fowler BJ. Accidental industrial laser burn of macula. Ann Ophthalmol. 1983;15:481-483.
2. Gabel VP, Birngruber R, Lorenz B. Clinical observations of six cases of laser injury to the eye. Health Phys. 1989;56:705-710.
3. Stuck BE, Zwick H, MolchanyJW, Lund DJ. Accidental human laser retinal injuries from military laser systems. SPIE. 1996;2674:7-20.
4. Wolbarsht ML. Permanent blindness from laser exposure in laboratory and industrial accidents. SPIE. 1996;2674:21-24.
5. Haifeng L, Guanghuang G, Dechang W. Ocular injuries from accidental laser exposure. Health Phys. 1989;56:711-716.
6. Mellerio J, Marshall J, Tebgroth B, Anderberg B, Wolbrasht, M. Battlefield laser weapons: An assessment of systems, hazards, injuries and ophthalmic resources required for treatment. Laser and Light in Ophthalmology. 1991;4:41-67.
7. Gibson KF, Kernoham W.G. Lasers in medicine: A review. J Med Eng Technol. 1993;17:51-7.
8. The National Society to Prevent Blindness. Highlights of Vision Problems in the U.S. U.S. Society to Prevent Blindness; 1979.
9. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37:1236-1249.
10. Green WR, Key SN. Senile macular degeneration: A histopathologic study. Tram Am Ophthalmol Soc. 1977;75:180-254.
11. The Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
12. The Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol. 1991;109:1242-1257.
13. The Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol. 1990;108:816-824.
14. Brancato R, Pece A, Avanza A, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-243.
15. Dastgheib K, Bressler SB, Green WR. Clinicopathologic correlation of laser lesion expansion after treatment of choroidal neovascularization. Retina 1993;13:345-352.
16. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-634.
17. Watkins JC, Evans RH. Excitatory amino acid transmitters. Ann Rev Pharmacol Toxicol. 1981;21:165-204.
18. Wroblewski JT, Danysz W. Modulation of glutamate receptors: Molecular mechanisms and functional implications. Ann Rev Pharmacol Toxicol. 1989;29:441-474.
19. Choi DW. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13:171-182.
20. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci. 1990;11:379-387.
21. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. Drug News Presp. 1995;8:261-273.
22. Kalloniatis M. Amino acids in neurotransmission and disease. J Am Optom Assoc. 1995;66:751-757.
23. Michaels RL, Rothman SM. Glutamate neurotoxicity in-vitro: Antagonist pharmacology and intracellular calcium concentrations. J Neurosci. 1990;10:283-292.
24. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci. 1987;10:299-302.
25. Schousboe A, Frandsen A, Wahl P, Krogsgaard-Larsen P. Neurotoxicity and excitatory amino acid antagonists. Neurotoxicology. 1994;15:477-481.
26. Faden AI, Salzman S. Pharmacological strategies in CNS trauma. Trends in Pharmacol Sci. 1992;13:29-35.
27. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
28. Scatton B. Excitatory amino acid receptor antagonists: A novel treatment for ischemic cerebrovascular diseases. Life Sci. 1994;55:2115-2124.
29. Reimherr FW, Wood DR, Wender PH. The use of MK- 801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol. 1986;22:237-242.
30. Rogawski MA, Poter RJ. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:23-285.
31. Barstable CJ. Glutamate and GABA in retinal circuitry. Curr Opin Neurobiol. 1993;3:520-525.
32. Brandon C, Man-Kit Lam D. A neurotransmitter candidate for cone photoreceptors in human and rat retinas. Proc Natl Acad Sci USA. 1983;80:5117-5121.
33. Linn DM, Balzynski C, Redburn DA, Massey SC. Acetylcholine release from the rabbit retina mediated by kainate receptors. J Neurosci. 1991;11:111-122.
34. Massey SC. Cell types using glutamate as a neurotransmitter in the vertebrate retina. In: Osborne NN, Chader GJ, eds. Progress in Retinal Research. Oxford: Pergamon Press; 1990:399-425.
35. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of human and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
36. Olney JW. The toxic effects of glutamate and related compounds in the retina and the brain. Retina. 1982;2:341-359.
37. Ulshafer RJ, Sherry DM, Dawson RJ, Wallace DR. Excitatory amino acid involvement in retinal degeneration. Brain Res. 1990;531:350-354.
38. Dreyer EB, Pan ZH, Storm S, Lipton SA, Greater sensitivity of large retinal ganglion cells to NMDA-mediated cell death. Neuroreport. 1994;5:5.
39. Sabel BA, Sautter J, Stoehr T, Silliprandi R. A behavioral model of excitotoxicity: Retinal degeneration, loss of vision, and subsequent recovery after intraocular NMDA administration in adult rats. Exp Brain Res. 1995;106:93-105.
40. Silliprandi R, Canella R, Carmignoto G, et al. N-Methyl-D-Aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567-573.
41. Sisk DR, Kuwabara T. Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate. Graefe's Arch Clin Exp Ophthalmol. 1985;223:250-258.
42. Asrar AM, Morse PH, Maimone D, Torczynski E, Reder AT. MK-801 protects retinal neurons from hypoxia and the toxicity of glutamate and aspartate. Invest Ophthalmol Vis Sci. 1992;33:3463-3468.
43. Levy DI, Lipton SA. Comparison of delayed administration of competitive and uncompetitive antagonists in preventing NMDA receptor-mediated neuronal death. Neurology. 1990;40:852-855.
44. Mosinger JL, Price MT, Bai HY, Xiao H, Wozniak DF, Olney JW. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neurol. 1991;113:10-17.
45. Sucher NJ, Aizenman E, Lipton SA. N-Methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro. J Neurosci. 1991;11:966-971.
46. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Invest Ophthalmol Vis Sci. 1996;37:1618-1624.
47. Marshall J, Bird AC. A comparative histopathological study of argon and krypton laser irradiations of the human retina. Br J Ophthalmol 1979;63:657-668.
48. Rosner M, Tchirkov M, Dubinski, G, Naveh N, Tso, MOM. Methylprednisolone ameliorates laser induced retinal injury in rats. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1996;37:S694.
49. Nyska A, Zuckerman A, Bar-Yosef A, et al. The application of image analysis as an aid in the evaluation of brain tissue damage: Two case studies. Isr J Vet Med. 1993;48:19-23.
50. Waner T, Baneth G, Zuckerman A, Nyska A. Hepatozoon canis: Size measurements of the gametocyte using image analysis technology. Comp Haematol Int. 1994;4:177-179.
51. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551.
52. Rutledge BK, Wallow IH, Poulsen GL. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol. 1993;111:608-613.
53. Schuschereba ST, Bowman PD, Ferrando RE, Lund DJ, Quong JA, Vargas JA. Accelerated healing of laser-injured rabbit retina by basic fibroblast growth factor. Invest Ophthalmol Vis Sci. 1994;35:945-954.
54. Cottrell JE. Possible mechanisms of pharmacological neuronal protection. J Neurosurg Anaesthesiol. 1995;7:31-37.
55. Lipton SA. Molecular mechanisms of trauma-induced neuronal degeneration. Curr Opin Neurol Neurosurg. 1993;6:588-596.
56. Peruche B, Krieglstein J. Mechanisms of drug actions against neuronal damage caused by ischemia: An overview. Prog Neuropsychopharmacol Biol Psych. 1993;17:21-70.
57. Siesjo BK. Mechanism of ischemic brain damage. Crit Care Med. 1988;16:954-963.
58. Ames A, Gurian BS. Effects of glucose and oxygen deprivation on function of isolated mammalian retina. J Neurophys. 1963;26:617-634.
59. Dowling JE. The Retina: An Approachable Part of the Brain. Cambridge: Belknap Press; 1987.
60. Cao W, Zaharia M, Drumheller A, et al. Effects of dextromethorphan on ischemia induced electroretinogram changes in rabbit. Curr Eye Res. 1994;13:97-102.
61. Gupta LY, Marmor MF. Mannitol, dextromethorphan and catalase minimize ischemic damage to retinal pigment epithelium and retina. Arch Ophthalmol. 1993;111:384-388.
62. Lombardi G, Moroni F, Moroni F. Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur J Pharmacol. 1994;271:489-495.
63. Sugawara T, Mon T, Kamei S, Tazawa Y. Protective effect of dextromethorphan on the ischemic retinal damage in rabbit. Nippon Ganka Gakki Zasshi. 1992;96:90-95.
64. Yoles E, Belkin M, Schwanz M. HU-211, a non-psychotropic cannabinoid, produces short and long-term neuroprotection after optic nerve axotomy. J Neurotrauma. 1996;13:49-57.
65. Bracken MB, Sheparo MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. N Engl J Med. 1990;322:1405-1411.
66. Faden AI. Pharmacotherapy in spinal cord injury: A critical review of recent development. Clin Neuropharmacol. 1987;10:193-204.
67. Azuma N, Kawamura M, Kohasaka S. Morphological and immunohistochemical studies on degenerative changes of the retina and the optic nerve in neonatal rat injected with monosodium-L-glutamate, Nippon Ganka Gakki Zasshi. 1989;93:72-79.
68. +2: Toxicity is blocked by the N-methyl-D-Aspartate antagonist MK-801. Proc Natl Acad Sci USA. 1988;85:6556-6560.
69. Sucher NJ, Lei SZ, Lipton SA. Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture. Brain Res. 1991;551:297-302.
70. Yoon YH, Marmor MF. Dextromethorphan protects retina against ischemic injury in vivo. Arch Ophthalmol. 1989;107:409-411.
71. Muller F, Greferath U, Wassle H, Wisden W, Seeburg P. Glutamate receptor expression in the rat retina. Neurosci Lett. 1992;138:179-182.
72. Bessho Y, Nawa H, Nakanishi S. Selective up-regulation of an NMDA receptor subunit mRNA in cultured cerebellar granule cells by K(+)-induced depolarization and NMDA treatment. Neuron. 1994;12:87-95.
73. Nakanishi S, Masu M, Bessho Y, Nakajima Y, Hayashi Y, Shigemoto R. Molecular diversity of glutamate receptors and their physiological functions. EXS. 1994;71:71-80.
74. Lindvall O, Ernfors P, Bengzon J, et al. Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proc Natl Acad Sci USA. 1992;89:648-652.
75. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, Lavail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature. 1990;347:83-86.
76. Lavail MM, Unoki K, Yasumura D, Matthes, MT, Yancopoulos GD, Steinberg RH. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci USA. 1992;89:11249-11253.
77. Ueda Y, Katsuta K, Nakanishi H, Yoshida K. Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995;185:107-110.
78. Facci L, Leon A, Skaper SD. Excitatory amino acid neurotoxicity in cultured retinal neurons: Involvement of N-methyl-D-aspartate (NMDA) and non-NMDA receptors and effect of ganglioside GM1. J Neurosci Res. 1990;27:202-210.
79. Uchida N, Kiuchi Y, Yamade M, et al. Glutamate-stimulated proliferation of rat retinal pigment epithelium through NMDA receptor activation and bFGF expression. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1996;37:S388.
80. Defoe DM, Matsumoto B, Besharse JC. Reconstitution of the photoreceptor-pigment epithelium interface: L-glutamate stimulation of adhesive interactions and rod disc shedding after recombination of dissociated Xenopus laevis eyecups. Exp Eye Res, 1992;54:903-911
81. Lopez-Colome AM, Fragoso G, Wright CE, Sturman JA. Excitatory amino acid receptors in membranes from cultured human retinal pigmented epithelium. Curr Eye Res. 1994;13:553-560.